FSFI endpoint is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
== Regulatory status == PRP is not regulated by the FDA because, like certain other human tissue and blood products, it is exempted from the traditional regulatory pathways; any use of PRP in a clinical setting is therefore considered "off label". The medical devices used to prepare PRP, however, are subject to FDA clearance.
=== Solution === Many growers resorted to their own methods in attempt to resolve the issue. Chemicals and pesticides were used to no avail. In desperation, some growers positioned toads under each vine, and others allowed their poultry to roam free in the hope they would eat the insects. None of these methods were successful. After Charles Valentine Riley, Missouri's state entomologist, confirmed Planchon's theory, Leo Laliman and Gaston Bazille, two French wine growers, both suggested the possibility that if vinifera vines could be combined, by means of grafting, with the aphid-resistant American vines, then the problem might be solved. Thomas Volney Munson was consulted and provided native Texan rootstocks for grafting. Because of Munson's role, the French government in 1888 sent a delegation to Denison, Texas, to confer on him the French Legion of Honor Chevalier du Mérite Agricole. Another viticulturist, Hermann Jaeger of Neosho, Missouri, was pivotal in the rescue of the French vineyards, as well. Jaeger working with the Missouri state entomologist George Hussman, had already raised vines with resistance to the pest. Indeed, several of the rootstalk varietals T.V. Munson had developed in Texas (Mrs Munson, Muench, and Neva Munson) were grafts with the hardy Neosho hybrids Jaeger had developed in Missouri. Jaeger exported 17 boxcars of his resistant rootstock to France.
Neanderthal pigmentation genes in modern non-African people are associated with both lighter and darker skin tones, as well as lighter and darker hair colors, suggesting Neanderthals themselves may have had variable pigmentation. Variants associated with red hair have been found in some Neanderthals, but they do not appear to have been common. Neanderthal skin and hair pigmentation variants are under positive selection in non-Africans, unlike most other Neanderthal genes, suggesting that the adaptive value of lighter features was beneficial for modern humans in Eurasia, where there is significantly less sunlight as compared to Africa.
The leaves are unique among seed plants, being fan-shaped with veins radiating out into the leaf blade, sometimes bifurcating (splitting), but never anastomosing to form a network. Two veins enter the leaf blade at the base and fork repeatedly in two; this is known as dichotomous venation. The leaves are usually 5–10 cm (2–4 in), but sometimes up to 15 cm (6 in) long. The old common name, maidenhair tree, derives from the leaves resembling pinnae of the maidenhair fern, Adiantum capillus-veneris. Ginkgos are prized for their autumn foliage, which is a deep saffron yellow. The species is heterophyllous (two types of leaves); those on the long shoots are thicker, have higher rates of photosynthesis, higher vein density and leaf hydraulic conductance, while those on the short shoots are better at handling drought. Leaves of long shoots are also usually notched or lobed, but only from the outer surface, between the veins. They are borne both on the more rapidly growing branch tips, where they are alternate and spaced out, and also on the short, stubby spur shoots, where they are clustered at the tips. Leaves are green both on the top and bottom and have stomata on both sides. During autumn, the leaves turn a bright yellow and then fall, sometimes within a short space of time (one to fifteen days). Leaves of the cultivar 'Tubifolia' have funnel-shaped leaves.
Sources: en.wikipedia.org
This broad classification is based on the empirical makeup and atomic structure of the solid materials, and most solids fall into one of these broad categories. An item that is often made from each of these materials types is the beverage container. The material types used for beverage containers accordingly provide different advantages and disadvantages, depending on the material used. Ceramic (glass) containers are optically transparent, impervious to the passage of carbon dioxide, relatively inexpensive, and are easily recycled, but are also heavy and fracture easily. Metal (aluminum alloy) is relatively strong, is a good barrier to the diffusion of carbon dioxide, and is easily recycled. However, the cans are opaque, expensive to produce, and are easily dented and punctured. Polymers (polyethylene plastic) are relatively strong, can be optically transparent, are inexpensive and lightweight, and can be recyclable, but are not as impervious to the passage of carbon dioxide as aluminum and glass.
Most specialties: the National Resident Matching Program (NRMP)—the American Osteopathic Association Match used to be a separate option for DOs but was merged with the NRMP Match after 2020 Urology Residency Match Program SF Match—ophthalmology, plastics Similarly, residency programs submit a list of their preferred applicants in rank order to this same service. The process is blinded, so neither applicant nor program will see each other's list. Aggregate program rankings can be found here, and are tabulated in real time based on applicants' anonymously submitted rank lists. The two parties' lists are combined by an NRMP computer, which creates stable (a proxy for optimal) matches of residents to programs using an algorithm. On the third Friday of March each year ("Match Day") these results are announced in Match Day ceremonies at the United States' 155 medical schools. By entering the Match system, applicants are contractually obligated to go to the residency program at the institution to which they were matched. The same applies to the programs; they are obligated to take the applicants who matched into them.
Ribosomally synthesized and post-translationally modified peptides (RiPPs), also known as ribosomal natural products, are a diverse class of natural products of ribosomal origin. Consisting of more than 20 sub-classes, RiPPs are found in all three domains of life, and they possess a wide range of biological functions. As a consequence of the falling cost of genome sequencing, scientific interest in RiPPs has increased in the last few decades. Because RiPPs are more closely predictable from raw genomic data than other natural products (e.g. alkaloids and terpenoids), their presence in sequenced organisms can, in theory, be identified rapidly. This makes RiPPs an attractive target of modern natural product discovery efforts.
=== Oil-water separation === Nanofibers have the capabilities in oil–water separation, most particularly in sorption process when the material in use has the oleophilic and hydrophobic surfaces. These characteristic enable the nanofibers to be used as a tool to combat either oily waste- water from domestic household and industrial activities, or oily seawater due to the oil run down to the ocean from oil transportation activities and oil tank cleaning on a vessel.
These traits include being born and living within the territorial borders of Israel or Judah, speaking Hebrew, living in specific house types, using locally produced pottery, and following particular burial practices. Israelites were also part of a rural kin-based society, and adhered to Yahwism, though not necessarily in a monotheistic way. Their material culture was simple but distinct, and their societal organization was centered around family and inheritance. These traits, while shared with some neighbouring peoples, were uniquely Israelite in their specific combination.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.